Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care

David Price; Arnaud Bourdin

Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care

Research output: Contribution to journal › Article › peer-review

5 Downloads (Pure)

Abstract

The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoing
overreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population. OCS Stewardship is a collaborative, systematic effort designed to protect patients with asthma from inappropriate OCS use through a series of patient- and physician focused initiatives. Ultimately, OCS Stewardship aims to reduce OCS-related morbidity, lower the risk of OCS-related adverse events (AE), increase health-related quality of life, and reduce healthcare resource utilisation.
This article summarises data that were exhibited as part of the European Respiratory Society (ERS) International Congress held in Barcelona, Spain, describing a novel proactive risk-management approach to embedding OCS Stewardship into asthma care. The objectives of this meeting were to highlight the latest data demonstrating the need for OCS Stewardship in asthma; discuss approaches to assessing OCS exposure and OCS-related toxicities, and the rationale for systematic assessment of OCS toxicity in individual patients; and to consider practical tools to evaluate future risk of asthma exacerbations and OCS-related adverse effects. Also described in this article are three posters, which were presented during the same meeting, and provide further data to support OCS-sparing activities in severe asthma by AstraZeneca.

Original language	English
Number of pages	10
Journal	European Medical Journal - Respiratory
Volume	10
Issue number	Supplement 2
Early online date	30 Nov 2022
Publication status	Published - 30 Nov 2022
Event	European Respiratory Society (ERS) International Congress. - FIRA Barcelona Gran Via Congress Centre, Barcelona, Spain Duration: 4 Sept 2022 → 6 Sept 2022 https://www.ersnet.org/congress-and-events/congress/

Bibliographical note

Acknowledgements: G. Walter Canonica, Professor of Respiratory Medicine at
the Humanitas Clinical and Research Center and Humanitas University, Milan, Italy, and Liam Heaney, Clinical Professor at Queen’s University, Belfast, Northern Ireland, presented alongside Price at the AstraZeneca-sponsored symposium, ‘Proactive risk management: a novel approach to embedding OCS Stewardship into asthma care’, delivered on 5th September 2022 at the ERS International Congress 2022 in Barcelona, 4th–6th September 2022. Writing assistance for this article was
provided by Rachel Danks, RSD Medical Communications Ltd, Gloucestershire, UK.

This is an AstraZeneca-funded publication summarising an AstraZeneca-sponsored symposium and three posters selected by AstraZeneca. This article is intended for HCPs

Access to Document

Price_etal_EMJR_Proactive_Risk_Management_VoR
Creative Commons Attribution-Non Comercial 4.0 https://creativecommons.org/licenses/by-nc/4.0
Final published version, 847 KBLicence: CC BY-NC

https://www.emjreviews.com/respiratory/journal/emj-respiratory-10-supplement-2-2022-s160222/Licence: CC BY-NC

Cite this

@article{7f79c2f33d2742a2b5d93e422d7255c2,

title = "Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care",

abstract = "The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoingoverreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population. OCS Stewardship is a collaborative, systematic effort designed to protect patients with asthma from inappropriate OCS use through a series of patient- and physician focused initiatives. Ultimately, OCS Stewardship aims to reduce OCS-related morbidity, lower the risk of OCS-related adverse events (AE), increase health-related quality of life, and reduce healthcare resource utilisation.This article summarises data that were exhibited as part of the European Respiratory Society (ERS) International Congress held in Barcelona, Spain, describing a novel proactive risk-management approach to embedding OCS Stewardship into asthma care. The objectives of this meeting were to highlight the latest data demonstrating the need for OCS Stewardship in asthma; discuss approaches to assessing OCS exposure and OCS-related toxicities, and the rationale for systematic assessment of OCS toxicity in individual patients; and to consider practical tools to evaluate future risk of asthma exacerbations and OCS-related adverse effects. Also described in this article are three posters, which were presented during the same meeting, and provide further data to support OCS-sparing activities in severe asthma by AstraZeneca.",

author = "David Price and Arnaud Bourdin",

note = "Acknowledgements: G. Walter Canonica, Professor of Respiratory Medicine at the Humanitas Clinical and Research Center and Humanitas University, Milan, Italy, and Liam Heaney, Clinical Professor at Queen{\textquoteright}s University, Belfast, Northern Ireland, presented alongside Price at the AstraZeneca-sponsored symposium, {\textquoteleft}Proactive risk management: a novel approach to embedding OCS Stewardship into asthma care{\textquoteright}, delivered on 5th September 2022 at the ERS International Congress 2022 in Barcelona, 4th–6th September 2022. Writing assistance for this article was provided by Rachel Danks, RSD Medical Communications Ltd, Gloucestershire, UK. This is an AstraZeneca-funded publication summarising an AstraZeneca-sponsored symposium and three posters selected by AstraZeneca. This article is intended for HCPs; European Respiratory Society (ERS) International Congress., ERS International Congress 2022 ; Conference date: 04-09-2022 Through 06-09-2022",

year = "2022",

month = nov,

day = "30",

language = "English",

volume = "10",

journal = "European Medical Journal - Respiratory",

number = "Supplement 2",

url = "https://www.ersnet.org/congress-and-events/congress/",

}

TY - JOUR

T1 - Proactive Risk Management

T2 - European Respiratory Society (ERS) International Congress.

AU - Price, David

AU - Bourdin, Arnaud

N1 - Acknowledgements: G. Walter Canonica, Professor of Respiratory Medicine at the Humanitas Clinical and Research Center and Humanitas University, Milan, Italy, and Liam Heaney, Clinical Professor at Queen’s University, Belfast, Northern Ireland, presented alongside Price at the AstraZeneca-sponsored symposium, ‘Proactive risk management: a novel approach to embedding OCS Stewardship into asthma care’, delivered on 5th September 2022 at the ERS International Congress 2022 in Barcelona, 4th–6th September 2022. Writing assistance for this article was provided by Rachel Danks, RSD Medical Communications Ltd, Gloucestershire, UK. This is an AstraZeneca-funded publication summarising an AstraZeneca-sponsored symposium and three posters selected by AstraZeneca. This article is intended for HCPs

PY - 2022/11/30

Y1 - 2022/11/30

N2 - The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoingoverreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population. OCS Stewardship is a collaborative, systematic effort designed to protect patients with asthma from inappropriate OCS use through a series of patient- and physician focused initiatives. Ultimately, OCS Stewardship aims to reduce OCS-related morbidity, lower the risk of OCS-related adverse events (AE), increase health-related quality of life, and reduce healthcare resource utilisation.This article summarises data that were exhibited as part of the European Respiratory Society (ERS) International Congress held in Barcelona, Spain, describing a novel proactive risk-management approach to embedding OCS Stewardship into asthma care. The objectives of this meeting were to highlight the latest data demonstrating the need for OCS Stewardship in asthma; discuss approaches to assessing OCS exposure and OCS-related toxicities, and the rationale for systematic assessment of OCS toxicity in individual patients; and to consider practical tools to evaluate future risk of asthma exacerbations and OCS-related adverse effects. Also described in this article are three posters, which were presented during the same meeting, and provide further data to support OCS-sparing activities in severe asthma by AstraZeneca.

AB - The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoingoverreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population. OCS Stewardship is a collaborative, systematic effort designed to protect patients with asthma from inappropriate OCS use through a series of patient- and physician focused initiatives. Ultimately, OCS Stewardship aims to reduce OCS-related morbidity, lower the risk of OCS-related adverse events (AE), increase health-related quality of life, and reduce healthcare resource utilisation.This article summarises data that were exhibited as part of the European Respiratory Society (ERS) International Congress held in Barcelona, Spain, describing a novel proactive risk-management approach to embedding OCS Stewardship into asthma care. The objectives of this meeting were to highlight the latest data demonstrating the need for OCS Stewardship in asthma; discuss approaches to assessing OCS exposure and OCS-related toxicities, and the rationale for systematic assessment of OCS toxicity in individual patients; and to consider practical tools to evaluate future risk of asthma exacerbations and OCS-related adverse effects. Also described in this article are three posters, which were presented during the same meeting, and provide further data to support OCS-sparing activities in severe asthma by AstraZeneca.

M3 - Article

VL - 10

JO - European Medical Journal - Respiratory

JF - European Medical Journal - Respiratory

IS - Supplement 2

Y2 - 4 September 2022 through 6 September 2022

ER -

Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this